Wikisage, the free encyclopedia of the second generation, is digital heritage
Diacomit: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 12: | Line 12: | ||
http://www.whocc.no/atc_ddd_index/?code=N03AX17 | http://www.whocc.no/atc_ddd_index/?code=N03AX17 | ||
{{refs}} | |||
[[Category: | |||
[[Category:GABAA_receptor_positive_allosteric_modulators]] | |||
Latest revision as of 23:36, 24 August 2020
Diacomit ®contains 250 mg stiripentol[1][2]
-Stiripentol_Structural_Formulae_V.1.svg.png)
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam[4]
ATC
http://www.whocc.no/atc_ddd_index/?code=N03AX17
| References: |
|